Survodutide

Most Common Uses

Survodutide, a dual glucagon receptor and glucagon-like peptide-1 receptor agonist, finds application in managing several metabolic conditions. Its primary use lies in treating type 2 diabetes mellitus, where it enhances glycemic control through improved insulin secretion and reduced glucagon release. The peptide also supports weight management in obesity, promoting satiety and increasing energy expenditure, which leads to significant body weight reduction. Additionally, Survodutide shows promise in addressing metabolic dysfunction-associated steatohepatitis (MASH), formerly known as non-alcoholic steatohepatitis, by reducing liver fat content and improving hepatic function. Ongoing clinical trials explore its potential in other metabolic disorders, reflecting its broad therapeutic versatility.

Mechanism of Action

Survodutide functions as a dual agonist, simultaneously activating glucagon receptors (GCGR) and glucagon-like peptide-1 receptors (GLP-1). Through GLP-1 activation, it enhances glucose-dependent insulin secretion from pancreatic beta cells, promoting better blood sugar regulation in type 2 diabetes. It also slows gastric emptying and increases satiety, contributing to appetite suppression and weight loss. Concurrently, GCGR activation stimulates glycogenolysis and gluconeogenesis in the liver, increasing energy expenditure and mobilizing stored fat. This dual action reduces liver fat accumulation, benefiting conditions like metabolic dysfunction-associated steatohepatitis (MASH). The peptide’s design, including a fatty acid conjugate, extends its plasma half-life to approximately six days, allowing once-weekly dosing. This balanced receptor engagement addresses multiple metabolic pathways, offering a comprehensive approach to managing diabetes, obesity, and related disorders.

Structure and Pharmacology

Survodutide, also known as BI 456906, is a synthetic 29-amino acid peptide designed to act as a dual agonist for glucagon receptors (GCGR) and glucagon-like peptide-1 receptors (GLP-1R). Its structure derives from the native glucagon sequence, with targeted modifications to enhance its therapeutic properties. Specific amino acid changes include substitutions at positions 18, 20, and 23 with GLP-1 residues, position 16 with an exendin-4 residue, and alterations at positions 24 and 27–29 to optimize receptor binding. A distinctive feature is the incorporation of 1-aminocyclobutane-1-carboxylic acid (Ac4c) at position 2, which enhances stability. The peptide also features C-terminal amidation and a C18 fatty diacid moiety conjugated via a hydrophilic linker at the lysine residue in position 24. This conjugation promotes strong binding to human serum albumin, extending the plasma half-life to approximately six days, which supports once-weekly administration.

Pharmacologically, Survodutide exhibits high potency in activating both GCGR and GLP-1R, achieving a balanced stimulation of these receptors. Its molecular weight is around 4232 g/mol, with a molecular formula of C192H289N47O61. The dual agonism facilitates improved glycemic control through GLP-1R-mediated insulin secretion and appetite suppression, while GCGR activation increases energy expenditure and reduces liver fat content. These effects make Survodutide effective for managing type 2 diabetes, obesity, and metabolic dysfunction-associated steatohepatitis (MASH). The extended half-life, driven by albumin binding (>99%), ensures sustained activity in plasma, offering consistent therapeutic benefits with less frequent dosing. Clinical studies highlight its favorable pharmacokinetic profile, with steady-state concentrations achieved after several weeks of subcutaneous administration.

Dosages

Survodutide is administered subcutaneously, typically on a once-weekly schedule due to its extended plasma half-life of approximately six days. Clinical trials have evaluated doses ranging from 0.1 mg to 2.4 mg per week, with common regimens involving gradual dose escalation to minimize gastrointestinal side effects. For type 2 diabetes and obesity management, patients often start with a lower dose, such as 0.6 mg weekly, increasing incrementally over several weeks to a maintenance dose of up to 4.8 mg or 6.0 mg, depending on therapeutic goals and tolerability.

In trials for metabolic dysfunction-associated steatohepatitis (MASH), similar dosing strategies have been employed, with adjustments based on patient response and clinical outcomes. Dosing schedules and maximum doses may vary based on ongoing research and regulatory approvals. Patients receive Survodutide via pre-filled syringes or pens, ensuring ease of administration.

Warnings and Cautions

Survodutide requires careful consideration due to potential risks. Patients with a history of pancreatitis should exercise caution, as glucagon-like peptide-1 receptor (GLP-1R) agonists may increase the likelihood of pancreatic inflammation. Monitoring for symptoms such as severe abdominal pain is advisable. The peptide carries a boxed warning for the risk of thyroid C-cell tumors, including medullary thyroid carcinoma, based on preclinical studies in rodents.

People with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 should avoid its use. Gastrointestinal side effects, including nausea, vomiting, and diarrhea, occur frequently, particularly during dose escalation, and may necessitate slower titration. Hypoglycemia risk increases when Survodutide is combined with insulin or sulfonylureas, requiring close glucose monitoring and potential dose adjustments of concomitant medications. Patients with severe renal or hepatic impairment should avoid using this peptide, as limited data exist on Survodutide’s safety in these populations.

Pregnant or breastfeeding women should avoid the drug due to insufficient safety data. Allergic reactions, including rash or anaphylaxis, have been reported, warranting immediate medical attention if symptoms arise. Regular monitoring and patient education on potential adverse effects enhance safe use.

Research & Clinical Trials

Phase 1 Trial of Survodutide

The study concluded that Survodutide is generally safe and well-tolerated in people with compensated or decompensated cirrhosis, including those with Child-Pugh class A, B, and C liver disease. Importantly, the pharmacokinetic profile, how the drug is absorbed, distributed, and eliminated, was similar in people with cirrhosis and healthy people, meaning no dose adjustment is needed based on liver function.

In the multi-dose portion of the trial, where participants received gradually increasing weekly doses up to 6.0 mg over 28 weeks, Survodutide led to reductions in liver fat, liver stiffness, liver volume, body weight, and other markers of liver and metabolic health. Adverse events, mostly gastrointestinal, were relatively common but manageable and occurred at similar rates in participants with and without cirrhosis.[1]

Phase 2 Trial of Survodutide

The study found that Survodutide worked much better than a placebo in improving a liver condition called MASH (a type of fatty liver disease linked to metabolic problems), without making liver scarring (fibrosis) worse over a 48-week period in adults who had confirmed MASH and moderate levels of fibrosis (stages F1 to F3).

The best results came from the 4.8 mg dose, where 62% of people showed improvement in their liver condition without worse scarring, compared to only 14% of those who got the placebo. Survodutide also helped lower liver fat in as many as 67% of participants and led to some improvement in liver scarring in up to 36%, although the liver fat improvement was more noticeable than the scarring improvement.

The most common side effects were related to the stomach and digestion, like nausea, diarrhea, and vomiting, and these happened more often in people taking Survodutide than in those taking the placebo. However, the number of serious side effects was about the same in both groups, 8% for Survodutide and 7% for the placebo. [2]

Phase 3 Trial of Survodutide

The study does not yet provide results or conclusions, as it describes the rationale and design of two ongoing Phase 3 clinical trials, SYNCHRONIZE-1 and SYNCHRONIZE-2, evaluating the investigational drug Survodutide.

These trials aim to assess the efficacy, safety, and tolerability of Survodutide, a dual glucagon and GLP-1 receptor agonist, for treating obesity with or without type 2 diabetes (T2D). Participants receive once-weekly injections of either Survodutide or a placebo alongside lifestyle modifications. The primary outcomes being measured are the percentage change in body weight and the proportion of participants achieving at least 5% weight loss after 76 weeks. Additional measures include changes in blood pressure, blood sugar control, and (in a substudy of SYNCHRONIZE-1) body composition and liver fat content using MRI.

In short, the study’s conclusion is not yet available, as these are ongoing trials. However, the trials are designed to generate strong evidence on whether Survodutide is an effective and safe treatment for obesity, both in people with and without T2D. [3]